Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)
Status:
Completed
Trial end date:
2021-01-12
Target enrollment:
Participant gender:
Summary
This is a prospective, phase 2, multicenter, randomized, double blind, placebo controlled,
parallel group study to assess the safety and efficacy of CSL312 administered intravenously,
in combination with standard of care (SOC) treatment, in patients with Coronavirus disease
2019 (COVID 19)